Monoclonal antibodies in the treatment of neuroimmunological diseases

Current Pharmaceutical Design

Volumn 18, Issue 29, 2012, Pages 4498-4507

  Rommer, Paulus S ^a   Patejdl, Robert ^b   Zettl, Uwe K ^b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF ROSTOCK   (Germany)

Author keywords

Alemtuzumab; Daclizumab; Immune mediated CNS disease; Monoclonal antibodies; Natalizumab; Rituximab

Indexed keywords

ABATACEPT; ADALIMUMAB; ALEFACEPT; ALEMTUZUMAB; BRIAKINUMAB; CANAKINUMAB; CERTOLIZUMAB PEGOL; CINQUIL; DACLIZUMAB; ECULIZUMAB; ETANERCEPT; GOLIMUMAB; IPILIMUMAB; MEPOLIZUMAB; MONOCLONAL ANTIBODY; NATALIZUMAB; OCRELIZUMAB; OFATUMUMAB; OMALIZUMAB; OTELIXIZUMAB; PRILIXIMAB; RESLIZUMAB; RITUXIMAB; SIFALIMUMAB; TEPLIZUMAB; TOCILIZUMAB; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; USTEKINUMAB;

ALLERGIC ASTHMA; ANKYLOSING SPONDYLITIS; ARTICLE; AUTOIMMUNE DISEASE; CHRONIC INFLAMMATORY DEMYELINATING POLYNEUROPATHY; CINCA SYNDROME; CROHN DISEASE; DERMATOMYOSITIS; ENTERITIS; EOSINOPHILIC ESOPHAGITIS; GOUT; GRAFT REJECTION; HUMAN; HYPEREOSINOPHILIC SYNDROME; IMMUNE MEDIATED INJURY; INCLUSION BODY MYOSITIS; INSULIN DEPENDENT DIABETES MELLITUS; JUVENILE RHEUMATOID ARTHRITIS; MELANOMA; MOTOR NEUROPATHY; MULTIPLE SCLEROSIS; MYASTHENIA GRAVIS; MYELOOPTIC NEUROPATHY; NEUROIMMUNOLOGICAL DISEASE; NEUROLOGIC DISEASE; NONHODGKIN LYMPHOMA; OPPORTUNISTIC INFECTION; OPSOCLONUS MYOCLONUS SYNDROME; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; POLYMYOSITIS; PRIORITY JOURNAL; PSORIASIS VULGARIS; PSORIATIC ARTHRITIS; RECEPTOR DOWN REGULATION; RECEPTOR UPREGULATION; RHEUMATOID ARTHRITIS; SIGNAL TRANSDUCTION; STIFF MAN SYNDROME; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; UNSPECIFIED SIDE EFFECT;

ANIMALS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; AUTOIMMUNE DISEASES OF THE NERVOUS SYSTEM; DRUG APPROVAL; DRUG DESIGN; HUMANS;

EID: 84866345794     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161212802502125     Document Type: Article

References (103)

1. Ehrlich P. Experimentelle Untersuchungen über Immunität. I. Ueber Ricin. Deutsche medizinische Wochenschrift 1891; 17: 976-979.
2. Köhler G, Milstein C. Continuous cultures of fused cells secreting antibody of predefined specificity. Nature 1975; 256: 495-497.
3. Li J, Zhu Z. Research and development of next generation of antibody- based therapeutics. Acta Pharmacol Sin 2010; 31: 1198-1207.
4. Rommer PS, Stüve O, Goertsches R, et al. Monoclonal antibodies in the therapy of multiple sclerosis: an overview. J Neurol 2008; 255 (Suppl. 6): 28-35.
5. Nelson AL, Dhimolea E, Reichert JM. Development trends for human monoclonal antibody therapeutics. Nat Rev Drug Discov 2010; 9: 767-774.
6. Lutterotti A, Martin R. Getting specific: monoclonal antibodies in multiple sclerosis. Lancet Neurol 2008; 7: 538-547.
7. Chan AC, Carter PJ. Therapeutic antibodies for autoimmunity and inflammation. Nat Rev Immunol 2010; 10: 301-316.
8. Gordon FH, Lai CW, Hamilton MI, et al. A randomized placebocontrolled trial of a humanized monoclonal antibody to alpha4 integrin in active Crohn's disease. Gastroenterology 2001; 121: 268-274.
9. http://www.fda.gov/NewsEvents/Newsroom/PressAnnouncements/2006/ucm108662.htm (released on June 6,2006)
10. O'Connor PW, Goodman A, Willmer-Hulme AJ, et al. Randomized multicenter trial of natalizumab in acute MS relapses: clinical and MRI effects. Neurology 2004; 62: 2038-2043.
11. Engelhardt B, Kappos L. Natalizumab: targeting alpha4-integrins in multiple sclerosis. Neurodegener Dis 2008; 5: 16-22.
12. Polman CH, O'Connor PW, Havrdova E, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899-910.
13. Rudick RA, Stuart WH, Calabresi PA, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med 2006; 354: 911-923.
14. Kleinschmidt-DeMasters BK, Tyler KL. Progressive multifocal leukoencephalopathy complicating treatment with natalizumab and interferon beta-1a for multiple sclerosis. N Engl J Med 2005; 353: 369-374.
15. Hellwig K, Gold R. Progressive multifocal leukoencephalopathy and natalizumab. J Neurol 2011; 258: 1920-1928.
16. Fernández O, García-Merino JA, Arroyo R, et al. Spanish consensus on the use of natalizumab (Tysabri(®)) - 2011. Neurologia 2011. 9 Nov (epub ahead of print)
17. Warnke C, Adams O, Hartung HP, et al. Risk stratification of progressive multiofocal leukoencephalopathy under natalizumab: recommendations for JC virus serology. Nervenarzt 2011 82(10): 1314-1319.
18. Magraner MJ, Coret F, Navarré A, et al. Pulsed steroids followed by glatiramer acetate to prevent inflammatory activity after cessation of natalizumab therapy: a prospective, 6-month observational study. J Neurol 2011; 258: 1805-1811.
19. Krumbholz M, Pellkofer H, Gold R, et al. Delayed allergic reaction to natalizumab associated with early formation of neutralizing antibodies. Arch Neurol 2007; 64: 1331-1333.
20. Bezabeh S, Flowers CM, Kortepeter C, et al. Clinically significant liver injury in patients treated with natalizumab. Aliment Pharmacol Ther 2010; 31: 1028-1035.
21. Hale G, Dyer MJ, Clark MR, et al. Remission induction in non- Hodgkin lymphoma with reshaped human monoclonal antibody CAMPATH-1H. Lancet 1988; 2: 1394-1399.
22. Flynn JM, Byrd JC. Campath-1H monoclonal antibody therapy. Curr Opin Oncol 2000; 12: 574-581.
23. Coles AJ, Cox A, Le Page E, et al. The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 2006; 253: 98-108.
24. Coles AJ, Fox E, Vladic A, et al. Alemtuzumab versus interferon beta-1a in early relapsing-remitting multiple sclerosis: post-hoc and subset analyses of clinical efficacy outcomes. Lancet Neurol 2011; 10: 338-348.
25. Hirst C, Raasch S, Llewelyn G, et al. Remission of chronic inflammatory demyelinating polyneuropathy after alemtuzumab (Campath 1H). J Neurol Neurosurg Psychiatry 2006; 77: 800-802.
26. Marsh EA, Hirst CL, Llewelyn JG, et al. Alemtuzumab in the treatment of IVIG-dependent chronic inflammatory demyelinating polyneuropathy. J Neurol 2010; 257: 913-919.
27. Dalakas MC, Rakocevic G, Schmidt J, et al. Effect of Alemtuzumab (CAMPATH 1-H) in patients with inclusion-body myositis. Brain 2009; 132: 1536-1544.
28. Reichert JM. Antibody-based therapeutics to watch in 2011. MAbs 2011; 3: 76-99.
29. Vollmer TL, Wynn DR, Alam MS, et al. A phase 2, 24-week, randomized, placebo-controlled, double-blind study examining the efficacy and safety of an anti-interleukin-12 and -23 monoclonal antibody in patients with relapsing-remitting or secondary progressive multiple sclerosis. Mult Scler 2011; 17: 181-191.
30. Bielekova B, Richert N, Howard T, et al. Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci U S A 2004; 101: 8705-8708.
31. Martin R. Humanized anti-CD25 antibody treatment with daclizumab in multiple sclerosis. Neurodegener Dis 2008; 5: 23-26.
32. Rose JW, Burns JB, Bjorklund J, et al. Daclizumab phase II trial in relapsing and remitting multiple sclerosis: MRI and clinical results. Neurology 2007; 69: 785-789.
33. Bielekova B, Howard T, Packer AN, et al. Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch Neurol 2009; 66: 483-489.
34. Wynn D, Kaufman M, Montalban X, et al. Daclizumab in active relapsing multiple sclerosis (CHOICE study): a phase 2, randomised, double-blind, placebo-controlled, add-on trial with interferon beta. Lancet Neurol 2010; 9: 381-390.
35. Biogen Idec. Phase III clinical trial using daclizumab for relapsingremitting multiple sclerosis initiated. Immunotherapy 2010; 2(4): 437.
36. Dold S, Justiniano ME, Marquez J, et al. Treatment of early and refractory dermatomyositis with infliximab: a report of two cases. Clin Rheumatol 2007; 26: 1186-1188.
37. Dastmalchi M, Grundtman C, Alexanderson H, et al. A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies. Ann Rheum Dis 2008; 67: 1670-1677.
38. van Oosten BW, Barkhof F, Truyen L, et al. Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. Neurology 1996; 47: 1531-1534.
39. Winkelmann A, Patejdl R, Wagner S, et al. Cerebral MRI lesions and anti-tumor necrosis factor-alpha therapy. J Neurol 2008; 255 Suppl 6: 109-114.
40. Mastaglia FL. Inflammatory muscle diseases. Neurol India 2008; 56: 263-270.
41. Bissonnette R, Papp K, Maari C, et al. A randomized, double-blind, placebo-controlled, phase I study of MEDI-545, an anti-interferonalfa monoclonal antibody, in subjects with chronic psoriasis. J Am cad Dermatol 2010; 62: 427-36.
42. Reid K. UPDATE 4-Roche, Biogen suspends arthritis drug after deaths.: http://www.reuters.com/article/2010/03/08/rocheidUSLDE62705720100308:.
43. Kappos L, Li D, Calabresi PA, et al. Ocrelizumab in relapsingremitting multiple sclerosis: a phase 2, randomised, placebocontrolled, multicentre trial. Lancet 2011; 378: 1779-1787.
44. Soelberg Sorensen P, Drulovic J, Havrdova E, et al. Magnetic resonance imaging (MRI) efficacy of ofatumumab in relapsingremitting multiple sclerosis (RRMS)-24-week results of a phase II study. Presented at: ECTRIMS; October 13-16, 2010; Gothenburg, Sweden. P136.
45. van Oosten BW, Lai M, Hodgkinson S, et al. Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: results of a randomized, double-blind, placebo-controlled, MR-monitored phase II trial. Neurology 1997; 49: 351-357.
46. Llewellyn-Smith N, Lai M, Miller DH, et al. Effects of anti-CD4 antibody treatment on lymphocyte subsets and stimulated tumor necrosis factor alpha production: a study of 29 multiple sclerosis patients entered into a clinical trial of cM-T412. Neurology 1997; 48; 810-816.
47. Rommer PS, Patejdl R, Winkelmann A, et al. Rituximab for secondary progressive multiple sclerosis: a case series. CNS Drugs 2011; 25: 607-613.
48. Wilk E, Witte T, Marquardt N, et al. Depletion of functionally active CD20+ T cells by rituximab treatment. Arthritis Rheum 2009; 60: 3563-3571.
49. Monson NL, Cravens P, Hussain R, et al. Rituximab therapy reduces organ-specific T cell responses and ameliorates experimental autoimmune encephalomyelitis. PLoS One 2011; 6: e17103.
50. Bar-Or A, Calabresi PAJ, Arnold D, et al. Rituximab in relapsingremitting multiple sclerosis: a 72-week, open-label, phase I trial. Ann Neurol 2008; 63: 395-400.
51. Hauser SL, Waubant E, Arnold DL, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med 2008; 358: 676-688.
52. Hawker K, O'Connor P, Freedman MS, et al. Rituximab in patients with primary progressive multiple sclerosis: results of a randomized double-blind placebo-controlled multicenter trial. Ann Neurol 2009; 66: 460-471.
53. Jacob A, Weinshenker BG, Violich I, et al. Treatment of neuromyelitis optica with rituximab: retrospective analysis of 25 patients. Arch Neurol 2008; 65: 1443-1448.
54. Cree B, Lamb S, Morgan K, et al. An open label study of the effects of rituximab in neuromyelitis optica. Neurology 2005; 64: 1270-1272.
55. Jarius S, Wildemann B. AQP4 antibodies in neuromyelitis optica: diagnostic and pathogenetic relevance. Nat Rev Neurol 2010; 6: 383-392.
56. Pranzatelli MR, Tate ED, Swan JA, et al. B cell depletion therapy for new-onset opsoclonus-myoclonus. Mov Disord 2010; 25: 238-242.
57. Leen WG, Weemaes CM, Verbeek MM, et al. Rituximab and intravenous immunoglobulins for relapsing postinfectious opsoclonus- myoclonus syndrome. Pediatr Neurol 2008; 39: 213-217.
58. Bell J, Moran CBlatt J. Response to rituximab in a child with neuroblastoma and opsoclonus-myoclonus. Pediatr Blood Cancer 2008; 50: 370-371.
59. Pranzatelli MR, Tate ED, Travelstead AL, et al. Rituximab (anti- CD20) adjunctive therapy for opsoclonus-myoclonus syndrome. J Pediatr Hematol Oncol 2006; 28: 585-593.
60. Pranzatelli MR, Tate ED, Travelstead AL, et al. Immunologic and clinical responses to rituximab in a child with opsoclonusmyoclonus syndrome. Pediatrics 2005; 115: e115-e119.
61. Yu Z, Kryzer TJ, Griesmann GE, et al. CRMP-5 neuronal autoantibody: marker of lung cancer and thymoma-related autoimmunity. Ann Neurol 2001; 49: 146-154.
62. Burke MJCohn SL. Rituximab for treatment of opsoclonusmyoclonus syndrome in neuroblastoma. Pediatr Blood Cancer 2008: 50: 679-680.
63. Briani C, Zara G, Zambello R, et al. Rituximab-responsive CIDP. Eur J Neurol 2004; 11: 788.
64. Kilidireas C, Anagnostopoulos A, Karandreas N, et al. Rituximab therapy in monoclonal IgM-related neuropathies. Leuk Lymphoma 2006; 47: 859-864.
65. Gorson KC, Natarajan N, Ropper AH, et al. Rituximab treatment in patients with IVIg-dependent immune polyneuropathy: a prospective pilot trial. Muscle Nerve 2007; 35: 66-69.
66. Rüegg SJ, Fuhr P, Steck AJ. Rituximab stabilizes multifocal motor neuropathy increasingly less responsive to IVIg. Neurology 2004; 63: 2178-2179.
67. Benedetti L, Briani C, Franciotta D, et al. Long-term effect of rituximab in anti-mag polyneuropathy. Neurology 2008; 71: 1742-1744.
68. Benedetti L, Briani C, Grandis M, et al. Predictors of response to rituximab in patients with neuropathy and anti-myelin associated glycoprotein immunoglobulin M. J Peripher Nerv Syst 2007; 12: 102-107.
69. Dalakas MC, Rakocevic G, Salajegheh M, et al. Placebo-controlled trial of rituximab in IgM anti-myelin-associated glycoprotein antibody demyelinating neuropathy. Ann Neurol 2009; 65: 286-293.
70. Renaud S, Fuhr P, Gregor M, et al. High-dose rituximab and anti- MAG-associated polyneuropathy. Neurology 2006; 66: 742-744.
71. Renaud S, Gregor M, Fuhr P, et al. Rituximab in the treatment of polyneuropathy associated with anti-MAG antibodies. Muscle Nerve 2003; 27: 611-615.
72. Pestronk A, Florence J, Miller T, et al. Treatment of IgM antibody associated polyneuropathies using rituximab. J Neurol Neurosurg Psychiatry 2003; 74: 485-489.
73. Broglio L, Lauria G. Worsening after rituximab treatment in antimag neuropathy. Muscle Nerve 2005; 32: 378-379.
74. Manto M, Laute M, Aguera M, et al. Effects of anti-glutamic acid decarboxylase antibodies associated with neurological diseases. Ann Neurol 2007; 61: 544-551.
75. Holmøy T, Geis C. The immunological basis for treatment of stiff person syndrome. J Neuroimmunol 2011; 231: 55-60.
76. Grant R, Graus F. Paraneoplastic movement disorders. Mov Disord 2009; 24: 1715-1724.
77. Dupond JL, Essalmi L, Gil H, et al. Rituximab treatment of stiffperson syndrome in a patient with thymoma, diabetes mellitus and autoimmune thyroiditis. J Clin Neurosci 2010; 17: 389-391.
78. Katoh N, Matsuda M, Ishii W, et al. Successful treatment with rituximab in a patient with stiff-person syndrome complicated by dysthyroid ophthalmopathy. Intern Med 2010; 49: 237-241.
79. Economides JRHorton JC. Eye movement abnormalities in stiff person syndrome. Neurology 2005; 65: 1462-1464.
80. Baker MR, Das M, Isaacs J, et al. Treatment of stiff person syndrome with rituximab. J Neurol Neurosurg Psychiatry 2005; 76: 999-1001.
81. Dalakas MC. Advances in the pathogenesis and treatment of patients with stiff person syndrome. Curr Neurol Neurosci Rep 2008; 8: 48-55.
82. Madaschi S, Rossini A, Formenti I, et al. Treatment of thyroidassociated orbitopathy with rituximab--a novel therapy for an old disease: case report and literature review. Endocr Pract 2010; 16: 677-685.
83. Bacorro EA, Tehrani R. Stiff-person syndrome: persistent elevation of glutamic acid decarboxylase antibodies despite successful treatment with rituximab. J Clin Rheumatol 2010; 16: 237-239.
84. Venhoff N, Rizzi M, Salzer U, et al. Monozygotic twins with stiff person syndrome and autoimmune thyroiditis: rituximab inefficacy in a double-blind, randomised, placebo controlled crossover study. Ann Rheum Dis 2009; 68: 1506-1508.
85. Fam AG. Recent advances in the management of adult myositis. Expert Opin Investig Drugs 2001; 10: 1265-1277.
86. Dalakas MC. B cells as therapeutic targets in autoimmune neurological disorders. Nat Clin Pract Neurol 2008; 4: 557-567.
87. Lindberg C, Bokarewa M. Rituximab for severe myasthenia gravis- -experience from five patients. Acta Neurol Scand 2010: 122: 225-228.
88. Farrugia ME, Vincent A. Autoimmune mediated neuromuscular junction defects. Curr Opin Neurol 2010; 23: 489-495.
89. Guptill JT, Sanders DB. Update on muscle-specific tyrosine kinase antibody positive myasthenia gravis. Curr Opin Neurol 2010: 23: 530-535.
90. Maddison P, McConville J, Farrugia ME, et al. The use of rituximab in myasthenia gravis and Lambert-Eaton myasthenic syndrome. J Neurol Neurosurg Psychiatry 2011; 82: 671-673.
91. Thakre M, Inshasi JMarashi M. Rituximab in refractory MuSK antibody myasthenia gravis. J Neurol 2007; 254: 968-969.
92. Baek WS, Bashey ASheean GL. Complete remission induced by rituximab in refractory, seronegative, muscle-specific, kinasepositive myasthenia gravis. J Neurol Neurosurg Psychiatry 2007; 78: 771.
93. Evoli A, Bianchi MR, Riso R, et al. Response to therapy in myasthenia gravis with anti-MuSK antibodies. Ann N Y Acad Sci 2008; 1132: 76-83.
94. Illa I, Diaz-Manera J, Rojas-Garcia R, et al. Sustained response to Rituximab in anti-AChR and anti-MuSK positive Myasthenia Gravis patients. J Neuroimmunol 2008: 201-202; 90-94.
95. Stieglbauer K, Topakian R, Schäffer V, et al. Rituximab for myasthenia gravis: three case reports and review of the literature. J Neurol Sci 2009: 280: 120-122.
96. Zebardast N, Patwa HS, Novella SP, et al. Rituximab in the management of refractory myasthenia gravis. Muscle Nerve 2010; 41: 375-378.
97. Díaz-Manera J, Rojas-García RIlla I. Treatment strategies for myasthenia gravis. Expert Opin Pharmacother 2009; 10: 1329-1342.
98. Zaja F, Russo D, Fuga G, et al. Rituximab for myasthenia gravis developing after bone marrow transplant. Neurology 2000; 55: 1062-1063.
99. Wylam ME, Anderson PM, Kuntz NL, et al. Successful treatment of refractory myasthenia gravis using rituximab: a pediatric case report. J Pediatr 2003; 143: 674-677.
100. Hain B, Jordan K, Deschauer M, et al. Successful treatment of MuSK antibody-positive myasthenia gravis with rituximab. Muscle Nerve 2006; 33: 575-580.
101. Longbrake EE, Racke MK. Why did IL-12/IL-23 antibody therapy fail in multiple sclerosis?. Expert Rev Neurother 2009; 9: 319-321.
102. Segal BM, Constantinescu CS, Raychaudhuri A, et al. Repeated subcutaneous injections of IL12/23 p40 neutralising antibody, ustekinumab, in patients with relapsing-remitting multiple sclerosis: a phase II, double-blind, placebo-controlled, randomised, doseranging study. Lancet Neurol 2008; 7: 796-804.
103. Verkman AS, Ratelade J, Rossi A, et al. Aquaporin-4: orthogonal array assembly, CNS functions, and role in neuromyelitis optica. Acta Pharmacol Sin 2011; 32: 702-710